Human CD19 Antibody

Name: Human CD19 Antibody
Brand: R&D Systems
SKU: MAB11516
Price: 169 USD
Availability: InStock

R&D Systems | Catalog # MAB11516

Submit a review

Citations (1)

Product Documents

Recombinant Monoclonal Antibody.

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 2978A

View all CD19 Primary Antibodies »

Product Specifications

Immunogen

Chinese Hamster Ovary cell line, CHO-derived human CD19
Met1-Lys291
Accession # P15391

Specificity

Detects human CD19 in Western blots.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for Human CD19 Antibody

Detection of Human CD19 by Western Blot.

Western Blot shows lysates of Raji human Burkitt's lymphoma cell line and NC‑37 human Burkitt's lymphoma B lymphoblast cell line. PVDF membrane was probed with 2 µg/ml of Rabbit Anti-Human CD19 Monoclonal Antibody (Catalog # MAB11516) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for CD19 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Applications for Human CD19 Antibody

Application

Recommended Usage

Western Blot

2 µg/mL
Sample: Raji human Burkitt's lymphoma cell line and NC-37 human Burkitt's lymphoma B lymphoblast cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from cell culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: CD19

CD19, also known as B4, is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 consists of an extracellular domain (ECD) with two C2-type Ig-like domains, a transmembrane segment, and a cytoplasmic domain with nine tyrosine residues, 3 of which are critical for function (1, 2). Within the mature ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre‑B cells through mature B cells, and it is commonly used as a B cell lineage marker (1, 2). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (1, 2). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu-13 (1, 3). These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR (1, 3). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials (6).